Bacterial outer membrane vesicles and vaccine applications

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Acevedo, Reinaldo ^a   Fernández, Sonsire ^a   Zayas, Caridad ^a   Acosta, Armando ^a   Sarmiento, Maria Elena ^a   Ferro, Valerie A ^b   Rosenqvist, Einar ^c   Campa, Concepcion ^a   Cardoso, Daniel ^a   Garcia, Luis ^a   Perez, Jose Luis ^a  

^a FINLAY INSTITUTE   (Cuba)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Adjuvant; Bordetella pertussis; Mycobacterium tuberculosis; Neisseria meningitidis; Outer membrane vesicles; Proteoliposomes; Vaccines; Vibrio cholerae

Indexed keywords

AG8GB ESAT 6 RECOMBINANT PROTEIN; BACTERIAL VACCINE; CROSS REACTING ANTIBODY; EARLY SECRETORY ANTIGENIC TARGET 6; ENDOTOXIN; FACTOR H BINDING PROTEIN; GAMMA INTERFERON; MENINGOCOCCUS VACCINE; NOD2 RECEPTOR; PEPTIDES AND PROTEINS; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VAX TYVI;

BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; HUMAN; IMMUNOGENICITY; MEMBRANE VESICLE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM SMEGMATIS; NEISSERIA MENINGITIDIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SHORT SURVEY; TUBERCULOSIS; VACCINATION; VIBRIO CHOLERAE;

EID: 84897934240     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00121     Document Type: Short Survey

References (54)

1. Lowell GH, Ripley BW, Smith LF, Wirtz RA, Zollinger WD, Hockmeyer WT. Proteasome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science (1988) 240:800-2. doi: 10.1126/science.2452484
2. Mesa C, de Leon J, Fernandez LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine (2006) 24(14):2692-9. doi:10.1016/j.vaccine.2005.01.114
3. Holst JD, Martin R, Campa C, Oster P, O'Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine (2009) 30S:B10-7. doi:10.1016/j.vaccine.2009.04.071
4. Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine (2009) 27S:B71-7. doi:10.1016/j.vaccine.2009.04.070
5. Van der Ley P, van den Dobbelsteen G. Next generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin (2011) 7(8):886-90. doi:10.4161/hv.7.8.16086
6. WHO. State of the Art of New Vaccine Research and Development. (2005). Available from:
7. Rodriguez T, Perez O, Ugrinovic S, Bracho G, Mastroeni P. Bacterial derived proteoliposome as ideal delivery system and cellular adjuvant. Vaccine (2006) 24(Suppl 2):24. doi:10.1016/j.vaccine.2005.01.106
8. Holst J, Oster P, Arnold R, Tatley MV, Næss LM, Aaberge IS, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother (2013) 9(6):1241-53. doi:10.4161/hv.24129
9. Miller JM, Mesaros N, Van Der Wielen M, Baine Y. Conjugate meningococcal vaccines development: GSK biologicals experience. Adv Prev Med (2011) 846756:1-17. doi:10.4061/2011/846756
10. Sierra G, Campa HC, Varcacel NM, Izquierdo PL, Sotolongo PF, Garcia L. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann (1991) 14:195-210.
11. Rosenqvist E, Høiby EA, Wedege E, Bryn K, Kolberg J. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun (1995) 63:4642-52.
12. Arnold R, Galloway Y, McNicholas A, O'Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine (2011) 29:7100-6. doi:10.1016/j.vaccine.2011.06.120
13. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther (2011) 11(7):969-85. doi:10.1517/14712598.2011.585965
14. Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine (2009) 27S:B42-50. doi:10.1016/j.vaccine.2009.05.001
15. Williams JN, Skipp PJ, Humphries HE, Christodoulides M, O'Connor D, Heckels JE. Proteomic analysis of outer membrane vesicles from wild type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect Immun (2007) 75(3):1364-72. doi:10.1128/IAI.01424-06
16. Van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, Martens D, et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine (2010) 28:4810-6. doi:10.1016/j.vaccine.2010.04.082
17. Norheim G, Tunheim G, Naess LM, Bolstad K, Fjeldheim AK, Garcia L, et al. A trivalent outer membrane vesicle (OMV) vaccine against serogroup A, W-135 and X meningococcal disease. XVIIIth International Pathogenic Neisseria Conference. Würzburg: Conventus Congress Management & Marketing GmbH (2012).
18. Tunheim G, Arnemo M, Næss LM, Fjeldheim AK, Nome L, Bolstad K, et al. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate-and polysaccharide vaccines. Vaccine (2013) 31:6097-106. doi:10.1016/j.vaccine.2013.09.044
19. Caugant DA, Kristiansen PA, Wang X, Mayer LW, Taha MK, Ouédraogo R, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One (2012) 7:e46019. doi:10.1371/journal.pone.0046019
20. Clinical trial of bivalent antimeningococcal vaccine candidate based on outer membrane vesicle AW135/Ensayo clinico con el candidato vacunal bivalente antimeningococico AW135 de Vesiculas de Membrana Externa. RPCEC (Cuban Public Register of Clinical Trials). Finlay Institute (2013). Available from: http://rpcec.sld.cu/ensayos/RPCEC00000160-Sp
21. Norheim G, Tunheim G, Næss LM, Kristiansen PA, Caugant DA, Rosenqvist E. An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt. Scand J Immunol (2012) 76(2):99-107. doi:10.1111/j.1365-3083.2012.02709.x
22. Caugant DA, Nicolas P. Molecular surveillance of meningococcal meningitis in Africa. Vaccine (2007) 25(Suppl 1):A8-11. doi:10.1016/j.vaccine.2007.04.033
23. Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine (2013) 31:2852-61. doi:10.1016/j.vaccine.2013.04.036
24. Perez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, et al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand J Immunol (2007) 66(2-3):271-7. doi:10.1111/j.1365-3083.2007.01981.x
25. Del Campo J, Lindqvist M, Cuello M, Bäckström M, Cabrerra O, Persson J, et al. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine (2010) 28:1193-200. doi:10.1016/j.vaccine.2009.11.035
26. Lastre M, Perez O, Labrada A, Bidot I, Perez J, Bracho G, et al. Bacterial derived proteoliposome for allergy vaccines. Vaccine (2006) 24(Suppl 2):S2-34. doi:10.1016/j.vaccine.2005.01.110
27. Subcutaneous immunotherapy with PROLINEM-Asthma-Adults-Fase I. RPCEC (Cuban Public Register of Clinical Trials). National Center of Bioproducts (2013). Available from: http://rpcec.sld.cu/trials/RPCEC00000139-En
28. Jones T, Cyr S, Allard F, Bellerose N, Lowel GH, Burt DS. Protollin™: a novel adjuvant for intranasal vaccines. Vaccine (2004) 22:3691-7. doi:10.1016/j.vaccine.2004.03.035
29. Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Safety and immunogenicity of a proteasome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun (2001) 69:4545-53. doi:10.1128/IAI.69.7.4545-4553.2001
30. Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L. Proteasome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Rev Vaccines (2011) 10(3):365-75. doi:10.1586/erv.10.172
31. Rohania P, Draked JM. The decline and resurgence of pertussis in the US. Epidemics (2011) 3:183-8. doi:10.1016/j.epidem.2011.10.001
32. Cherry JD. Epidemic pertussis in 2012. The resurgence of a vaccine-preventable disease. N Engl J Med (2012) 367:785-7. doi:10.1056/NEJMp1209051
33. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis (2013) 56:1248. doi:10.1093/cid/cit046
34. Fernández S, Fajardo EM, Mandiarote A, Año G, Padrón MA, Acosta M, et al. A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models. BMC Immunol (2013) 14(Suppl 1):S8. doi:10.1186/1471-2172-14-S1-S8
35. Asensio CJ, Gaillard ME, Moreno G, Bottero D, Zurita E, Rumbo M, et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine (2011) 29(8):1649-56. doi:10.1016/j.vaccine.2010.12.068
36. Roberts R, Moreno G, Bottero D, Gaillard ME, Fingermann M, Graieb A, et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine (2008) 26(36):4639-46. doi:10.1016/j.vaccine.2008.07.004
37. Perez JL, Acevedo R, Callico A, Fernandez Y, Cedre B, Ano G, et al. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine (2009) 27(2):205-12. doi:10.1016/j.vaccine.2008.10.052
38. Schild S, Nelson EJ, Camilli A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun (2008) 76(1):4554-63. doi:10.1128/IAI.00532-08
39. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem (2002) 71:635-700. doi:10.1146/annurev.biochem.71.110601.135414
40. Pérez JL, Callicó A, Fernández S, Reyes G, Cabreras R, Acosta M, et al. Preliminary characterization of an oral multivalent vaccine candidate against Cholera-Shigella-Salmonella. Vaccimonitor (2009) 18(1):7.
41. Callicó A, Reyes G, Fernández S, Cabrera R, Acosta M, Aranguren Y, et al. Proteoliposomes derived from Escherichia coli induced systemic and mucosal response. Vaccimonitor (2010) 19(1):32.
42. Camacho AI, de Souza J, Sánchez-Gómez S, Pardo-Ros M, Irache JM, Gamazo C. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice. Vaccine (2011) 29:8222-9. doi:10.1016/j.vaccine.2011.08.121
43. Acevedo R, Callicó A, Aranguren Y, Zayas C, Valdés Y, Pérez O, et al. Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi. BMC Immunol (2013) 14(Suppl 1):S10. doi:10.1186/1471-2172-14-S1-S10
44. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (2003) 83(1):91-7. doi:10.1016/S1472-9792(02)00089-6
45. Coulombe F, Divangahi M, Veyrier F, Léséleuc L, Gleason JL, Yang Y, et al. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med (2009) 206(8):1709. doi:10.1084/jem.20081779
46. Jeon BY, Kim HJ, Jo EK, Park JK, Paik TH, Kim SJ, et al. Protection of mice against Mycobacterium tuberculosis infection by immunization with aqueous fraction of triton X-100-soluble cell proteins. Scand J Inmunol (2008) 67(1):18-23. doi:10.1111/j.1365-3083.2007.02031.x
47. Hamasur B, Haile M, Pawlowski A, Schröder U, Williams A, Hatch G, et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine (2003) 21:4081-93. doi:10.1016/S0264-410X(03)00274-3
48. Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) (2006) 86(3-4):273-89. doi:10.1016/j.tube.2006.01.024
49. Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, Perrie Y. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res (2009) 19(1):2-11. doi:10.1080/08982100902726820
50. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, et al. Cationic liposomes formulated with synthetic mycobacterial cord factor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One (2008) 3(9):e3116. doi:10.1371/journal.pone.0003116
51. Barker LF, Chen V, Meyer D, Rosenstein PK, Brennan MJ. New tuberculosis vaccines: what is in the pipeline? In: Acosta A, Nor NM, Sarmiento ME editors. The Art and Science of Tuberculosis Vaccine Development. Oxford: Oxford University Press (2010).
52. Reyes F, Tirado Y, Puig A, Borrero R, Reyes G, Fernández S, et al. Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG. BMC Immunol (2013) 14(Suppl 1):S7. doi:10.1186/1471-2172-14-S1-S7
53. Rodriguez L, Tirado Y, Reyes F, Puig A, Kadir R, Borrero R, et al. Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine (2011) 29(37):6236-41. doi:10.1016/j.vaccine.2011.06.077
54. Acosta A, Kadir R, Ahmad F, Puig A, Borrero R, Garcia M, et al. Development of experimental strategies for the prophylaxis and treatment of tuberculosis. Latinfarma. Havana: (2013).